Shares of Shionogi & Co., Ltd. (OTCMKTS:SGIOY - Get Free Report) hit a new 52-week high during trading on Monday . The company traded as high as $8.49 and last traded at $8.37, with a volume of 74866 shares traded. The stock had previously closed at $8.28.
Shionogi & Co., Ltd. Stock Down 0.5 %
The stock has a market cap of $14.24 billion, a PE ratio of 14.52, a price-to-earnings-growth ratio of 2.37 and a beta of 0.21. The company has a quick ratio of 7.01, a current ratio of 7.64 and a debt-to-equity ratio of 0.01. The firm has a fifty day moving average of $7.73 and a 200 day moving average of $7.26.
Shionogi & Co., Ltd. (OTCMKTS:SGIOY - Get Free Report) last released its quarterly earnings results on Friday, January 31st. The company reported $0.16 EPS for the quarter. Shionogi & Co., Ltd. had a net margin of 35.53% and a return on equity of 12.02%. On average, equities research analysts anticipate that Shionogi & Co., Ltd. will post 0.66 EPS for the current fiscal year.
About Shionogi & Co., Ltd.
(
Get Free Report)
Shionogi & Co, Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug.
Featured Articles
Before you consider Shionogi & Co., Ltd., you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Shionogi & Co., Ltd. wasn't on the list.
While Shionogi & Co., Ltd. currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
